{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:40:05Z","timestamp":1759038005550,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.psychres.2018.05.014","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T21:44:58Z","timestamp":1526679898000},"page":"25-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Use of antipsychotic blood levels in clinician decision making: A cross-over study using clinical vignettes of patients with schizophrenia"],"prefix":"10.1016","volume":"267","author":[{"given":"Adam","family":"Savitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Melkote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A","family":"Pobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"McQuarrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Banderas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.psychres.2018.05.014_bib0001","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00002281-200203000-00006","article-title":"Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research","volume":"14","author":"Beaton","year":"2002","journal-title":"Curr. Opin. Rheumatol."},{"issue":"2-3","key":"10.1016\/j.psychres.2018.05.014_bib0002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.psychres.2004.11.002","article-title":"A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia","volume":"133","author":"Byerly","year":"2005","journal-title":"Psychiatry Res"},{"issue":"2 Pt 1","key":"10.1016\/j.psychres.2018.05.014_bib0003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00019053-199712020-00003","article-title":"The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings","volume":"12","author":"Evans","year":"1997","journal-title":"PharmacoEconomics"},{"issue":"6","key":"10.1016\/j.psychres.2018.05.014_bib0004","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2165\/00019053-200017060-00002","article-title":"Expert judgement in pharmacoeconomic studies. Guidance and future use","volume":"17","author":"Evans","year":"2000","journal-title":"PharmacoEconomics"},{"issue":"4","key":"10.1016\/j.psychres.2018.05.014_bib0005","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/23.4.637","article-title":"Determinants of medication compliance in schizophrenia: empirical and clinical findings","volume":"23","author":"Fenton","year":"1997","journal-title":"Schizophr. Bull."},{"year":"1981","series-title":"Statistical Methods for Rates and Proportions,","author":"Fleiss","key":"10.1016\/j.psychres.2018.05.014_bib0006"},{"issue":"4","key":"10.1016\/j.psychres.2018.05.014_bib0007","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1176\/appi.ajp.161.4.692","article-title":"Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia.","volume":"161","author":"Gilmer","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2018.05.014_bib0008","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/77.4.371","article-title":"Methods to explain the clinical significance of health status measures","volume":"77","author":"Guyatt","year":"2002","journal-title":"Mayo Clin. Proc."},{"issue":"5","key":"10.1016\/j.psychres.2018.05.014_bib0009","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2018.05.014_bib0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"year":"1975","series-title":"The Delphi Method: Techniques and Applications","author":"Linstone","key":"10.1016\/j.psychres.2018.05.014_bib0011"},{"issue":"10","key":"10.1016\/j.psychres.2018.05.014_bib0012","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.4088\/JCP.12117tx2c","article-title":"Monitoring treatment and managing adherence in schizophrenia","volume":"74","author":"Marder","year":"2013","journal-title":"J. Clin. Psychiatry"},{"year":"1994","series-title":"The Assessment of Reliability","author":"Nunnally","key":"10.1016\/j.psychres.2018.05.014_bib0013"},{"issue":"Suppl 4","key":"10.1016\/j.psychres.2018.05.014_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.7090su1cj","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2018.05.014_bib0015","first-page":"426","article-title":"Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments, and prospects","volume":"27","author":"Young","year":"1999","journal-title":"J. Am. Acad. Psychiatry Law"},{"issue":"10","key":"10.1016\/j.psychres.2018.05.014_bib0016","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1176\/appi.ajp.159.10.1653","article-title":"Interventions to improve medication adherence in schizophrenia","volume":"159","author":"Zygmunt","year":"2002","journal-title":"Am. J. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117316803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117316803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:25:47Z","timestamp":1759037147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178117316803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":16,"alternative-id":["S0165178117316803"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2018.05.014","relation":{},"ISSN":["0165-1781"],"issn-type":[{"type":"print","value":"0165-1781"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of antipsychotic blood levels in clinician decision making: A cross-over study using clinical vignettes of patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2018.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Janssen Research & Development, LLC. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}